This article is more than 5 years old. Information may no longer be current.

VIDEO: Novel BRAF/MEK combination shows ‘best-in-class’ efficacy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Keith T. Flaherty, MD, medical oncologist at Massachusetts General Hospital Cancer Center, spoke with HemOnc Today at ASCO Annual Meeting about results from the COLUMBUS trial.

The phase 3 trial assessed the combination of encorafenib (LGX818, Array BioPharma) — a BRAF inhibitor — and binimetinib (MEK162, Array BioPharma), a MEK inhibitor, for patients with advanced BRAF-mutated melanoma.

In the three-arm study, researchers compared the combination with the historical standard — vemurafenib (Zelboraf, Genentech) monotherapy — as well as encorafenib monotherapy.

Data presented at ASCO showed the encorafenib-binimetinib combination significantly extended OS compared with both monotherapy regimens.

“[With encorafenib and binimetinib], we’re looking at best-in-class efficacy outcomes with PFS and OS, and best-in-class tolerability, making us believe this is probably a very welcome addition to the treatment of our patients,” Flaherty told HemOnc Today.